PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a study for the outcome and safety of individualized busulfan dosing with
cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat
Non-Hodgkin or Hodgkin's Lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
Center for International Blood and Marrow Transplant Research